Xiao-Shi Zhang

2.2k total citations
39 papers, 1.8k citations indexed

About

Xiao-Shi Zhang is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Xiao-Shi Zhang has authored 39 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 20 papers in Immunology and 18 papers in Molecular Biology. Recurrent topics in Xiao-Shi Zhang's work include Immune Cell Function and Interaction (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Immunotherapy and Immune Responses (7 papers). Xiao-Shi Zhang is often cited by papers focused on Immune Cell Function and Interaction (9 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Immunotherapy and Immune Responses (7 papers). Xiao-Shi Zhang collaborates with scholars based in China, Sweden and United States. Xiao-Shi Zhang's co-authors include Yi-Xin Zeng, Jiang Li, Jun Cui, Jia He, Bi-Jun Huang, Dong-Hua Luo, Rui-Qing Peng, Zhi-Zhong Pan, Ya Ding and Qiu-Yan Chen and has published in prestigious journals such as PLoS ONE, Cell Death and Differentiation and PLoS Pathogens.

In The Last Decade

Xiao-Shi Zhang

39 papers receiving 1.7k citations

Peers

Countries citing papers authored by Xiao-Shi Zhang

Since Specialization

Citations

This map shows the geographic impact of Xiao-Shi Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiao-Shi Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiao-Shi Zhang more than expected).

Fields of papers citing papers by Xiao-Shi Zhang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiao-Shi Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiao-Shi Zhang. The network helps show where Xiao-Shi Zhang may publish in the future.

Co-authorship network of co-authors of Xiao-Shi Zhang

This figure shows the co-authorship network connecting the top 25 collaborators of Xiao-Shi Zhang. A scholar is included among the top collaborators of Xiao-Shi Zhang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiao-Shi Zhang. Xiao-Shi Zhang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Down Regulation of c-FLIPL Enhance PD-1 Blockade Efficacy in B16 Melanoma 2019 ·Frontiers in Oncology ·Yao Wang, Jingjing Li, (unknown), (unknown), (unknown), Dandan Li, Xiao‐Feng Zhu, Xiao-Shi Zhang	12
2	STING signaling remodels the tumor microenvironment by antagonizing myeloid-derived suppressor cell expansion 2019 ·Cell Death and Differentiation ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Hai-Qiang Mai, Qiu-Yan Chen, Jia He, Xiao-Shi Zhang, Yi-Xin Zeng, Jiang Li, Jun Cui	100
3	Sphingosine 1 phosphate receptor-1 (S1P1) promotes tumor-associated regulatory T cell expansion: leading to poor survival in bladder cancer 2019 ·Cell Death and Disease ·(unknown), Han Zhang, Lin Zhang, (unknown), (unknown), Jia He, (unknown), Fang-Jian Zhou, Xiao-Shi Zhang, Jiang Li	40
4	Rejection of adenovirus infection is independent of coxsackie and adenovirus receptor expression in cisplatin-resistant human lung cancer cells 2016 ·Oncology Reports ·(unknown), Rui-Qing Peng, Ya Ding, Xiao-Shi Zhang	6
5	Safety of immune checkpoint inhibitors in Chinese patients with melanoma 2016 ·Melanoma Research ·Xizhi Wen, Yao Wang, Ya Ding, Dandan Li, Jingjing Li, Yiqun Guo, Ruiqing Peng, Jingjing Zhao, Xing Zhang, Xiao-Shi Zhang	21
6	Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma: a novel prognostic indicator 2015 ·Cancer Immunology Immunotherapy ·Han Zhang, (unknown), (unknown), (unknown), (unknown), Jia He, Hui-Qiang Huang, Yi-Xin Zeng, Xiao-Shi Zhang, Jiang Li	77
7	Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma 2015 ·Medical Oncology ·(unknown), Ya Ding, Dandan Li, Jingjing Li, Rui-Qing Peng, (unknown), Xing Zhang, Xiao-Shi Zhang	5
8	Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer 2015 ·Journal of Translational Medicine ·(unknown), Xiao-Jun Wu, (unknown), Rongxin Zhang, (unknown), Wei Liao, Zhi-Zhong Pan, Limin Zheng, Xiao-Shi Zhang, Zhong Wang, Qing Li, Gang Ma, Jiang Li	158
9	CD33+/p-STAT1+ double-positive cell as a prognostic factor for stage IIIa gastric cancer 2013 ·Medical Oncology ·Jun Dong, (unknown), (unknown), (unknown), Shi Chen, Yingbo Chen, Xiao-Shi Zhang	28
10	The prognostic value of platelet endothelial cell adhesion molecule-1 in non-small-cell lung cancer patients 2013 ·Medical Oncology ·(unknown), (unknown), Ya Ding, Rui-Qing Peng, Pei‐Qiang Cai, (unknown), Feng Jiang, Xiao-Shi Zhang, Xing Zhang	17
11	The absence of the ERBB4 hotspot mutations in melanomas in patients from southern China 2012 ·Chinese Journal of Cancer ·(unknown), Wěi Li, (unknown), Xing Zhang, (unknown), Ya Ding, (unknown), Rui-Qing Peng, Shu-Mei Yan, Xiao-Shi Zhang	5
12	A pilot study of paclitaxel combined with gemcitabine followed by interleukin-2 and granulocyte macrophage colony-stimulating factor for patients with metastatic melanoma 2012 ·Cancer Biology & Therapy ·Rui-Qing Peng, Ya Ding, Xing Zhang, Yuan Liao, Limin Zheng, Xiao-Shi Zhang	4
13	Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells 2011 ·Chinese Journal of Cancer ·Yao Wang, Rui-Qing Peng, Dandan Li, Ya Ding, Xiao-Qi Wu, Yi-Xin Zeng, Xiao‐Feng Zhu, Xiao-Shi Zhang	54
14	Mast cells in adjacent normal colon mucosa rather than those in invasive margin are related to progression of colon cancer 2011 ·Chinese Journal of Cancer Research ·Qing Xia, Ya Ding, Xiao-Jun Wu, Rui-Qing Peng, Qiang Zhou, Jing Zeng, Jing-Hui Hou, Xing Zhang, Yi-Xin Zeng, Xiao-Shi Zhang, Yingbo Chen	8
15	Rhabdastrellic Acid-A Induced Autophagy-Associated Cell Death through Blocking Akt Pathway in Human Cancer Cells 2010 ·PLoS ONE ·Dandan Li, (unknown), Jia-Jia Huang, Linlin Wang, Rong Deng, (unknown), Gong-Kan Feng, (unknown), (unknown), Xiao-Shi Zhang, Xiao‐Feng Zhu	29
16	Adjuvant interferon therapy for malignant melanoma:the debate 2010 ·Chinese Journal of Cancer ·(unknown), Xiao-Shi Zhang	3
17	Proteasome inhibitor MG-132 modifies coxsackie and adenovirus receptor expression in colon cancer cell line lovo 2008 ·Cell Cycle ·(unknown), Li-Bing Song, Xiao-Jun Wu, (unknown), Mu‐Sheng Zeng, Xiao‐Feng Zhu, De-Sen Wan, (unknown), Yi-Xin Zeng, Xiao-Shi Zhang	17
18	Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine 2007 ·Cancer Immunology Immunotherapy ·Ji-yan Liu, Yang Wu, Xiao-Shi Zhang, (unknown), (unknown), (unknown), Yi Wang, (unknown), Yong-Qiang Li, Jian‐Chuan Xia, Maria G. Masucci, Yi-Xin Zeng	106
19	V-val subtype of Epstein-Barr virus nuclear antigen 1 preferentially exists in biopsies of nasopharyngeal carcinoma 2004 ·Cancer Letters ·Xiao-Shi Zhang, (unknown), Li–Fu Hu, Ang Li, Ru-Hua Zhang, Hai-Qiang Mai, Jian‐Chuan Xia, (unknown), Yi-Xin Zeng	48
20	The 30-bp deletion variant: a polymorphism of latent membrane protein 1 prevalent in endemic and non-endemic areas of nasopharyngeal carcinomas in China 2002 ·Cancer Letters ·Xiao-Shi Zhang, (unknown), Hai-Qiang Mai, Wei-Hua Jia, Bing Feng, Jian‐Chuan Xia, Ru-Hua Zhang, Li-Xi Huang, Xing-Juan Yu, Qi-Sheng Feng, (unknown), (unknown), Yi-Xin Zeng	52

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact